*For medical professionals only
I have been a doctor all my life, and I am very pleased!
Written by | Fan Shuhao Jian Yu Su
Source | "Medical Community" public account
He is the director of the Harbin Institute of Hematology and Oncology, the chairman of the supervisory board of the Chinese Society of Clinical Oncology, and the vice chairman of the Asian Society of Clinical Oncology. At the same time, he is also an "ordinary" doctor who has devoted himself to clinical practice for more than 50 years, a strivers who have worked hard to create "atypical" success, and an "old naughty boy" with a straightforward personality and a cheerful laugh. Ma Jun, who is now over 70 years old, told the "medical community" about his medical experience and the development and changes of Chinese tumors in his eyes.
"Let me be a doctor for the rest of my life, and I'll come back!"
In 1970, Ma Jun was assigned to the laboratory of the First Hospital of Harbin, and he worked hard to complete the basic courses of the university and master the relevant clinical medicine and laboratory technology. With this "tenacity", Professor Ma Jun obtained the opportunity to study in Japan and became the first batch of public students sent by the mainland after the reform and opening up.
Figure 1 Professor Ma Jun working in the laboratory
Years later, Ma Jun talked about his study abroad experience is still exciting: "Among our classmates who studied abroad, I am the youngest. In foreign countries, I felt that there is still a big gap between our country's medical technology and the world's advanced level, and I wanted to learn the most advanced technology and bring it back to serve China's blood patients. ”
In 1982, Professor Ma Jun returned to China after completing his studies and became a veritable "fragrant feast". At that time, major scientific research institutes and well-known hospitals in Beijing, Shanghai and other places had warmly invited each other, hoping to retain this rare returnee talent in the field of hematology and tumors. Sometimes even a national leader asked him to stay in the health system and do government work.
Figure 2 Professor Ma Jun studying in Japan
At that time, ma jun's hometown, the provincial and municipal leaders of the Heilongjiang provincial health system, also threw him an "olive branch": hoping that he could lead the establishment of an independent blood disease research institute in Harbin.
In the 1980s, Harbin, located in northeast China, was not rich, and its hard conditions and soft power were not as good as the developed areas of "north, Shanghai and Guangzhou". After repeated weighing, in the spirit of the simple feeling of repaying the hometown, Professor Ma Jun chose to return to Harbin, but only made one request. "Let me be a doctor for a lifetime, and I will come back as a clinical researcher for a lifetime!"
In this way, Professor Ma Jun used his valuable life experience of up to 52 years in the frontline clinical position to fulfill his commitment at that time.
Anything,
It cannot be more important than saving the lives of patients
In 1971, when Han Taiyun, a pharmacist at the First Hospital of Harbin Medical University, took root in Lindian County, Heilongjiang Province, he found that a rural doctor used "arsenic" topical compresses to treat a variety of diseases in the affected area, and the pain was significantly alleviated after the patient's medication, and the anemia symptoms were alleviated, and good efficacy was achieved. After the intensive research of Han Taiyun pharmacist and a number of medical workers of the older generation, the "arsenic cream" was finally purified and named "Cancer Spirit No. 1", and the injection "713" was developed for clinical application.
Professor Ma Jun and his medical team took the lead in applying this therapy to the treatment of patients with relapsed refractory acute promyelocytic leukemia (M3), and achieved remarkable therapeutic results. The first leukemia patients treated with this drug from 1971 to 1973 are still healthy today.
From the 1970s to 1990, the new treatment had an 82 percent cure rate for M3 leukemia, and since 1996, it has been 92 percent. Since then, the "poison" in the eyes of the people has officially become a "good medicine" to cure leukemia.
Nowadays, the Harbin Blood Research Institute founded by Professor Ma Jun has treated more than 100,000 patients with hemolymphatic system tumors, especially in the treatment of patients with M3 leukemia and recurrent refractory leukemia.
During the epidemic period, Harbin Blood Institute has treated more than 15,000 patients with blood diseases with zero infections among medical staff. The young doctor at the institute said: "As long as he is in the hospital, it is his outpatient time at any time." As long as time permits, he never refuses a patient's request for medical treatment. ”
Ma Jun laughed and said, "I walk very fast, they always say that I am very much like a young man!" I usually don't have a day off, I never go to a special needs clinic, and my number is always a regular number of 5 yuan to 20 yuan. Many people are very difficult to see a doctor, some people hang an expert outpatient number of 1000 yuan, but you must know that it is possible that this patient will take the only 1,000 yuan to come to you for treatment. ”
Professor Ma Jun loves to laugh, but sometimes he will be angry, and this "anger" is nothing more than two things: the patient's treatment plan cannot be delayed, and the time to treat the patient cannot be delayed.
He has been furious that young doctors have delayed patients' treatment for "meetings." "The purpose of our party is to serve the people wholeheartedly. Our doctors' aim is to serve our patients wholeheartedly. No matter what it is, no matter what important person it is, as long as the patient needs it, it can be pushed away. Nothing can go beyond the patient's life! ”
Help and witness the rapid development of the blood field
The history of blood diseases is very long, but the history of really becoming a specialist is very short. In 1915, an internist from the Rockefeller Group in the United States first reported the discovery of a special case of "malnutrition anemia" in China, which was also the first report of blood-related diseases in the mainland. It was not until the establishment of the Union Hospital that the hospital had the so-called "Puneke", at which time the blood system diseases were arranged to be treated in the "Punnai".
After the founding of the People's Republic of China, the first generation of pioneers in the diagnosis and treatment of blood diseases in the mainland, represented by Professor Deng Jiadong, Professor Chen Yueshu, Professor Yu Zhifei and Professor Pan Ruipeng, established the first generation of hematology specialties in Suzhou, Shanghai, Tianjin and Beijing.
After the founding of the People's Republic of China, especially after the reform and opening up, the development of hematology and oncology specialties in the mainland has been very rapid. In 1982, under the presidency of Professor Ma Jun, the Harbin Institute of Hematology and Oncology was formally established. At the same time, academician Wang Zhenyi, professor Shen Zhixiang, professor Deng Jiadong, professor Chen Wenjie, and academician Lu Daopei presided over the four major blood research institutes in China were established one after another. In 1996, the Chinese Society of Clinical Oncology (CSCO) was established with the support of Professor Sun Yan, Academician Wu Mengchao, Professor Liao Meilin and Professor Guan Zhongzhen. It has become another milestone in the development of the field of clinical oncology diagnosis and treatment in mainland China.
"Today, about 17.8% of the international research project leaders of the global medical community's hematology oncology specialty are Chinese. At asCO, ESMO, ASH, JSMO and other internationally renowned oncology-related seminars, Chinese researchers have been all over the world, often blowing 'Chinese wind'. After decades of unremitting efforts, the level of tumor diagnosis and treatment of large comprehensive medical centers in mainland China has ranked among the forefront in the world. I feel fortunate to be in it, to participate in and witness the development of the field of hematological oncology in the mainland. Professor Ma Jun had a confident smile on his face.
Up to now, Professor Ma Jun has trained nearly 86 master's and doctoral students in the field of hematology and tumors in mainland China, and the footprints of students' learning and practice have spread all over the world. Although peach and plum are all over the world, "but I chose to stay here, I also want to be an example for the young doctors who hope to stay." ”
Asked how young doctors are now facing heavy clinical work and scientific pressures, they are developing. Professor Ma Jun told us about the 18-character proverb he adhered to. "Have kindness, patience, determination, patience, hardship, willingness to study." "I hope that our young generation of hematology and oncologists will unite, innovate and collaborate." At the same time, treat patients with kindness, and do everything for the sake of patients' lives and health. As long as we are obsessed with thinking about patients, so that they can get psychological comfort, symptom relief and even clinical cure, this is the greatest thing we do as doctors! ”
Expert Profiles
Ma
Chief Physician, Professor, Doctoral Supervisor
Director of Harbin Institute of Hematology and Oncology
Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO).
Vice Chairman of the Asian Society of Clinical Oncology
Chairman of the Leukemia Expert Committee of the Chinese Society of Clinical Oncology
Leader of the Expert Group of the Lymphoma Specialist Construction Project of the Capacity Building and Continuing Education Center of the National Health Commission
Honorary Consultant of the Nursing Group of the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology
In 1979, he went to the Faculty of Medicine of the University of Tokyo in Japan to study, and has been committed to the diagnosis and treatment of benign and malignant diseases of the blood system, especially for the treatment of leukemia and lymphoma. In 1982, the first in vitro multi-energy hematopoietic progenitor cell culture system was established in China to fill the domestic gap. Since 1983, more than 1,200 cases of acute promyelocytic leukemia have been treated with tretinoin and arsenic trioxide sequential therapy, and the 10-year disease-free survival rate is 85%, reaching the international advanced level. He has published more than 200 papers and more than 40 monographs in domestic and foreign journals, and won 20 national, provincial and municipal science and technology awards. He has undertaken 8 national 863 major scientific research projects and 25 provincial and municipal scientific research projects.
Source: Medical community
Editor-in-charge: Wang Hang
Proofreader: Zang Hengjia